People dont want to get it treated or diagnosed, and women very often are missed, as well as those who dont meet the stereotypical apnea type of an overweight, older, white male
Food and Drug Administration (FDA) updated its guidance, mandating the assessment of all new T2D therapies in long-term CV outcomes trials (CVOTs), in addition to the requirement for registrational studies demonstrating improvements in glycaemic control [13]
Sierra-cinos JL, Seguido MA, Gonz S
For the majority of protocols particularly those involving sustained dosing, combination with GHRH analogs, or body composition endpoints ipamorelin's selectivity advantage outweighs GHRP-6's potency advantage
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial